Neuromyelitis optica spectrum disorder (NMOSD), an inflammatory disease of the central nervous system, manifests as optic neuritis, myelitis, and certain brain and brainstem syndromes. Recent ...
Multiple treatment transitions in patients with neuromyelitis optica spectrum disorder (NMOSD) for nonmedical reasons are associated with increased neurological harm, including relapse risk and ...
People with AQP4-IgG seropositive NMOSD, who are treatment-naïve or where prior rituximab (or biosimilar) treatment has failed, will be administered Enspryng monotherapy for two years and evaluated ...
Results from CHAMPION-NMOSD trial demonstrated ULTOMIRIS reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo ULTOMIRIS also showed a lower proportion of patients experiencing ...
"The key learning from this work is that timely treatment transitions may hold equatable benefit to the prescribed treatments themselves… the time between moving from one treatment to another was ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In the last year, three therapies were ...
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that mostly affects your eyes and spinal cord. Your immune system attacks a specific protein, called aquaporin-4 (AQP4). The ...
Enspryng is a new treatment approved for both adults and adolescents with AQP4-IgG seropositive NMOSD in the EU. It is the first treatment approved in the EU for adolescents from 12 years of age with ...
BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results